PPD Updates 2007 Forecast; Issues Financial Guidanc...(quality to help its clients and partners...),Health
quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations
and assumptions contained in this news release, including the projected net
revenue, earnings, milestone payments, and capital spending guidance for
2008, are forward-looking statements that involve a number of risks and
uncertainties. Although PPD attempts to be accurate in making these
forward- looking statements, it is possible that future circumstances might
differ from the assumptions on which such statements are based. In
addition, other important factors which could cause actual results to
differ materially include the following: continued success in sales growth;
loss of large contracts; increased cancellation rates; failure or refusal
of the FDA to accept or approve the NDA for alogliptin, risks associated
with the development and commercialization of drugs, including earnings
dilution and obtaining regulatory approvals; risks associated with and
dependence on collaborative relationships; the ability to attract and
retain key personnel; rapid technological advances that make our products
and services less competitive; economic conditions and outsourcing trends
in the pharmaceutical, biotechnology and medical device industries and
academic and government- sponsored research sectors; competition within the
outsourcing industry; risks associated with acquisitions and investments,
such as impairments; and the other risk factors set forth from time to time
in the SEC filings for PPD, copies of which are available free of charge
upon request from the PPD investor relations department.
Contacts:
Dan Darazsdi
+910 558 7915
dan.darazsdi@wilm.ppdi.c
'/>"/>
| SOURCE PPD, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Cardiome Updates Guidance
2. Silverchair Learning Systems Updates and Develops New Courses
3. eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook
6. WallSt.net (www.wallst.net) Updates the Investment Community Through All-New Interviews With XMDC, POSS and TYPE
7. WallSt.net Updates Investment Community Through All-New Interview With XTend Medical
8. WallSt.net Updates Investment Community Through All-New Interview With Ingen Technologies
9. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
10. West Pharmaceutical Services Updates Annual Guidance
11. ADA Updates Environmental Recommendations for Handling Waste
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |